BiotechTube
InnoMedica

InnoMedica

Lucerne, Switzerland· Est.
innomedica.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $17.5M

Overview

InnoMedica is a private, clinical-stage biotech leveraging a proprietary nanotechnology platform for targeted drug delivery. Its most advanced program is a potentially novel therapy for Parkinson's disease, which is in Phase II clinical development, with a parallel oncology program demonstrating the platform's versatility. The company has established its own GMP-certified manufacturing facility ('Nanofactory') in Switzerland and is currently executing a capital increase round to fund development through 2025.

NeurologyOncology

Technology Platform

Proprietary liposomal nanocarrier platform for targeted delivery and controlled release of active ingredients (small molecules, RNA, proteins) to enhance efficacy and reduce side effects.

Funding History

2
Total raised:$17.5M
Series A$15M
Seed$2.5M

Opportunities

The platform addresses a fundamental drug delivery challenge, creating opportunities across multiple therapeutic areas with high unmet need, particularly in neurology and oncology.
Success in the lead Parkinson's program could enable valuable late-stage partnerships and validate the platform for broader external collaboration.

Risk Factors

High clinical development risk associated with proving efficacy and safety of novel nanotherapies.
Financial dependency on successful capital raises in a competitive funding environment.
Significant competition in the drug delivery and nanomedicine space from larger, well-funded entities.

Competitive Landscape

InnoMedica operates in the highly competitive nanomedicine and targeted drug delivery sector, competing with both large pharmaceutical companies with internal capabilities and numerous biotech startups. Differentiation hinges on demonstrating superior clinical performance, manufacturing expertise, and intellectual property around its specific liposomal formulation technology.

More companies in Switzerland →